If this is not your name, click here.
| | If this is not your name, click here. | | |
| | Contact Us | Order Now | Journals | Bookstore | Register a colleague | | |
| |  FDA Approves Reintroduction of Inversine (Mecamylamine) for Tourette's Syndrome SUNNYVALE, CA -- May 15, 2000 -- Layton BioScience, Inc., a biotechnology company that specializes in developing innovative therapies for neurological disorders, has received approval from the United States Food and Drug Administration to reintroduce Inversine(R) (mecamylamine HCl) to the U.S. market. Inversine(R), a nicotinic receptor antagonist, was formulated for the treatment of hypertension. Launched in the 1950s, Inversine (R) was one of the first orally active antihypertensives on the U.S. market. "Inversine has a long history of use, almost a half century," states Gary Snable, Layton's chief executive officer. "We believe our studies will show that it has applications for treating a number of neurological disorders." Currently, Layton is studying Inversine(R) for use in treating symptoms of Tourette Syndrome (TS), which include motor and vocal tics and mood disorders. A case report on the use of Inversine(R) to treat Tourette Syndrome was published in The Lancet in August 1998, and a two-year retrospective study will be published this June in the Journal of Child and Adolescent Psychopharmacology. A new, 18-month study on the use of Inversine(R) in combination with neuroleptic medications is scheduled to begin later this year at the University of South Florida and the University of Florida. In March, the University of South Florida and researchers Archie A. Silver, M.D., Paul R. Sanberg, Ph.D., D.Sc., and R. Douglas Shytle, Ph.D., received United States Patent #6034079 for the use of nicotine antagonists to treat nicotine-responsive neuropsychiatric disorders. The patent stems from earlier research they conducted with the nicotine patch. Layton has an exclusive, worldwide license to develop therapeutics based on the patent. In addition, Layton has an active discovery program focusing on finding new chemical entities selective for the nicotinic receptors that are designed to provide targeted and increasingly effective new medications. Layton also has clinical programs focused on the use of nicotinic receptor antagonists in the treatment of addictions (nicotine, cocaine and alcohol) and other neuropsychiatric indications. Layton BioScience, Inc., with offices in Sunnyvale, Calif., and Radnor, Pa., is a biopharmaceutical company devoted to developing therapies for treating diseases of the central nervous system and neuropsychiatric disorders. The company is currently conducting clinical trials on stroke patients with its stem-cell-like LBS-Neurons(TM), and has obtained the exclusive license to engraftable human neural stem cells, which have applications for global disorders such as Alzheimer's disease. Layton's network of scientists in universities across the United States are researching therapies for other debilitating diseases such as spinal cord injury, brain tumors, Parkinson's disease, Huntington's disease and Tay-Sachs disease.
|
